drugset

drugset / Trial / NCT00083239

Study of Talabostat in Advanced Melanoma

NCT00083239 ↗

Phase 2 Completed Point Therapeutics

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the antitumor activity and safety of talabostat in patients with metastatic melanoma.

Timeline

Start: —
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	talabostat	Small molecule	—	—

Indications